Canaccord Genuity Reiterates $18.00 Price Target for Karyopharm Therapeutics Inc. (KPTI)

Canaccord Genuity set a $18.00 price objective on Karyopharm Therapeutics Inc. (NASDAQ:KPTI) in a report issued on Tuesday, August 8th. The firm currently has a buy rating on the stock.

Several other brokerages also recently issued reports on KPTI. Cantor Fitzgerald restated an overweight rating and issued a $18.00 price objective on shares of Karyopharm Therapeutics in a research report on Monday, May 15th. Zacks Investment Research downgraded Karyopharm Therapeutics from a buy rating to a hold rating in a research report on Tuesday, July 18th. Jefferies Group LLC reiterated a buy rating and set a $16.00 target price on shares of Karyopharm Therapeutics in a research report on Friday, July 14th. ValuEngine downgraded Karyopharm Therapeutics from a hold rating to a sell rating in a research report on Thursday, May 25th. Finally, Robert W. Baird reiterated an outperform rating and set a $15.00 target price on shares of Karyopharm Therapeutics in a research report on Tuesday, July 4th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $14.56.

Karyopharm Therapeutics (KPTI) traded up 0.74% on Tuesday, hitting $8.21. The stock had a trading volume of 107,618 shares. Karyopharm Therapeutics has a one year low of $6.27 and a one year high of $14.63. The stock’s 50 day moving average is $8.95 and its 200 day moving average is $9.94. The stock’s market cap is $387.00 million.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.64). Karyopharm Therapeutics had a negative return on equity of 70.42% and a negative net margin of 67,267.47%. During the same period in the prior year, the company earned ($0.84) EPS. Karyopharm Therapeutics’s revenue for the quarter was down 95.0% compared to the same quarter last year. Analysts anticipate that Karyopharm Therapeutics will post ($2.69) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.com-unik.info/2017/08/19/karyopharm-therapeutics-inc-kpti-given-a-18-00-price-target-at-canaccord-genuity-updated.html.

Several large investors have recently bought and sold shares of the stock. Teza Capital Management LLC bought a new stake in Karyopharm Therapeutics during the first quarter worth about $169,000. Voya Investment Management LLC raised its stake in Karyopharm Therapeutics by 42.1% in the second quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock worth $136,000 after buying an additional 4,444 shares during the period. Tudor Investment Corp ET AL bought a new stake in Karyopharm Therapeutics during the second quarter worth about $136,000. American International Group Inc. raised its stake in Karyopharm Therapeutics by 20.9% in the first quarter. American International Group Inc. now owns 16,422 shares of the company’s stock worth $211,000 after buying an additional 2,836 shares during the period. Finally, C WorldWide Group Holding A S raised its stake in Karyopharm Therapeutics by 30.2% in the first quarter. C WorldWide Group Holding A S now owns 16,928 shares of the company’s stock worth $217,000 after buying an additional 3,928 shares during the period. Institutional investors and hedge funds own 57.58% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

What are top analysts saying about Karyopharm Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Karyopharm Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit